98%
921
2 minutes
20
Objective: Our study aims to establish the potential for tumor heterogeneity evaluated using F fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) texture analysis in nonsmall-cell lung carcinoma (NSCLC) patients who underwent platinum-based chemotherapy to provide an independent marker for overall survival (OS) of more than 1-year.
Materials And Methods: A total of 42 patients (34 male and 8 female) with biopsy-proven NSCLC and mean age 55.33 ± 10.71 years who underwent a baseline F-18 FDG PET/CT and received platinum-based chemotherapy as first-line treatment were retrospectively included in the study. Ten first order, 21 s order texture parameters and 7 SUV and metabolic tumor volume (MTV) based metabolic parameters were calculated. All these parameters were compared between the two survival groups based on OS ≥1 year and OS <1 year. Cut-offs of significant parameters were determined using receiver operating characteristic curve analysis. Survival patterns were compared by log-rank test and presented using Kaplan-Meier curves. Cox proportion hazard model was used to determine the independent prognostic marker for 1 year OS.
Results: In univariate survival analysis, 3 first order texture parameters (i.e. mean, median, root mean square with hazard ratios [HRs] 2.509 [ = 0.034], 2.590 [ = 0.05], 2.509 [ = 0.034], respectively) and 6 s order texture parameters (i.e. mean, auto correlation, cluster prominence, cluster shade, sum average and sum variance with HRs 2.509 [ = 0.034], 2.509 [ = 0.034], 3.929 [0.007], 2.903 [0.018], 2.954 [0.016] and 2.906 [0.014], respectively) were significantly associated with 1 year OS in these patients. Among the metabolic parameters, only metabolic tumor volume whole-body was significantly associated with 1 year OS. In multivariate survival analysis, cluster prominence came out as the independent predictor of 1 year OS.
Conclusion: Texture analysis based on F-18 FDG PET/CT is potentially beneficial in the prediction of OS ≥1 year in NSCLC patients undergoing platinum-based chemotherapy as first-line treatment. Thus, can be used to stratify the patients which will not be benefitted with platinum-based chemotherapy and essentially needs to undergo some other therapy option.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481851 | PMC |
http://dx.doi.org/10.4103/ijnm.ijnm_20_21 | DOI Listing |
Int J Clin Oncol
September 2025
Department of Urology, University of Tsukuba Institute of Medicine, Tsukuba, Ibaraki, 305-8575, Japan.
Metastatic urothelial carcinoma (mUC) remains a disease with poor prognosis. While conventional platinum-based chemotherapy has long served as the standard first-line treatment, its survival benefit is limited, particularly in cisplatin-ineligible patients. The introduction of immune checkpoint inhibitors and antibody-drug conjugates as part of sequential treatment has improved outcomes, with pembrolizumab, avelumab, and enfortumab vedotin (EV) providing survival benefit in later lines.
View Article and Find Full Text PDFJ Oncol Pharm Pract
September 2025
Department of Toxicology, Showa Medical University Graduate School of Pharmacy, Tokyo, Japan.
IntroductionOxaliplatin is a platinum-based drug widely used for treating colorectal cancer. However, its use is often complicated by hypersensitivity reactions and other adverse effects, including peripheral neuropathy and myelosuppression. We evaluated the efficacy of prophylactic hydrocortisone administration in preventing hypersensitivity reactions during oxaliplatin therapy in patients with colorectal cancer.
View Article and Find Full Text PDFCureus
August 2025
Medical Oncology, Mohammed VI University Hospital of Marrakech, Marrakesh, MAR.
Sebaceous carcinoma of the breast is a rare and poorly understood variant of metaplastic breast carcinoma. Its histogenesis, clinical behavior, and optimal management remain unclear due to the limited number of reported cases. We report the case of a 78-year-old woman presenting with a six-month history of a right axillary mass and inflammatory changes in the right breast.
View Article and Find Full Text PDFCureus
August 2025
Dermatology, Centro Medico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City, MEX.
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT), is an uncommon and aggressive subtype of cutaneous B-cell lymphoma, typically affecting elderly women and predominantly involving the lower extremities. Its diagnosis relies on immunohistochemical profiling and clinical presentation. We report a rare case of a 45-year-old male presenting initially with scalp and supraciliary plaques.
View Article and Find Full Text PDFGynecol Oncol Rep
October 2025
Obstetrics and Gynecology Institute, Cleveland Clinic Foundation, Cleveland OH, United States.
Objective: Carcinosarcoma an aggressive subtype of ovarian cancer. While treatment consists primarily of cytoreductive surgery followed by platinum-based chemotherapy, maintenance therapy can also be considered. Limited data exists on the use of poly ADP-ribose polymerase (PARP) inhibitors in ovarian carcinosarcoma, though this has been anecdotally successful among a small number of patients.
View Article and Find Full Text PDF